U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07674667) titled 'FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS' on June 21.
Brief Summary: The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal injection). The trial will also assess how the body processes the drug and whether it shows early signs of benefit over 24 weeks.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Later...